FDA Plans Rare Advisory Hearing to Debate Moderna’s Flu Shot

Moderna Inc.’s experimental flu shot made with mRNA technology will be reviewed by a Food and Drug Administration advisory panel next month, a sign that the agency may be increasing transparency into its decision-making after several controversies.

Advisory panel hearings, once a standard part of the approval process for new medical therapies, have been rare during the second Trump administration. Moderna’s review is scheduled for June 18, according to a notice published Thursday. The FDA is slated to make an approval decision by Aug. 5.

In February, the FDA shocked Wall Street and the biotech industry by initially refusing ...